Loading company…
Yellowstone Bioscience develops T-cell therapies for AML and other cancers.
Based in Oxford, UK, Yellowstone Bioscience develops T-cell-specific therapeutics for acute myeloid leukaemia and other HLA-II-expressing cancers. Its research draws on a biobank of over 10,000 samples from more than 3,000 AML patients. Co-founded by Paresh Vyas (CSO) and Julian Hirst (CFO), the company raised GBP 16.5 million in Series A funding in June 2024, led by Syncona Limited.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in